Targeted Therapy for Malignant Glioma Patients: Lessons Learned and the Road Ahead

Neurotherapeutics

Volumn 6, Issue 3, 2009, Pages 500-512

  Huang, Tiffany T ^a   Sarkaria, Shawn M ^a   Cloughesy, Timothy F ^a   Mischel, Paul S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

coactivation; Glioma; growth factors; microenvironment; molecular targeted therapy

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AFLIBERCEPT; AM 7; AMG 102; ANTINEOPLASTIC AGENT; ARQ 197; BEVACIZUMAB; CE 355621; CEDIRANIB; CETUXIMAB; DASATINIB; DN 30; ERLOTINIB; GEFITINIB; HYDROXYUREA; IMATINIB; IMC A12; JNJ 38877605; LAPATINIB; MK 2461; MONOCLONAL ANTIBODY 806; MP 470; NIMOTUZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; XL 184;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG TARGETING; FEEDBACK SYSTEM; GLIOBLASTOMA; HUMAN; LYMPHOMA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; STOMACH TUMOR;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; FEEDBACK, BIOCHEMICAL; GLIOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 67649084009     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.04.008     Document Type: Article

References (125)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Bishop J.M. Molecular themes in oncogenesis. Cell 64 (1991) 235-248
3. Bruna A., Darken R.S., Rojo F., et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11 (2007) 147-160
4. Yoshida D., Kim K., Noha M., and Teramoto A. Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 76 (2006) 13-21
5. Arrieta O., Garcia E., Guevara P., et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 94 (2002) 3210-3218
6. Koochekpour S., Jeffers M., Rulong S., et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57 (1997) 5391-5398
7. Uchinokura S., Miyata S., Fukushima T., et al. Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo. Int J Cancer 118 (2006) 583-592
8. Reznik T.E., Sang Y., Ma Y., et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 6 (2008) 139-150
9. Huang H., Held-Feindt J., Buhl R., Mehdorn H.M., and Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol Res 27 (2005) 371-377
10. Ningaraj N.S., Rao M.K., and Black K.L. Adenosine 5′-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res 63 (2003) 8899-8911
11. Cerletti A., Drewe J., Fricker G., Eberle A.N., and Huwyler J. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Target 8 (2000) 435-446
12. Deguchi Y., Kurihara A., and Pardridge W.M. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjug Chem 10 (1999) 32-37
13. Badruddoja M.A., and Black K.L. Improving the delivery of therapeutic agents to CNS neoplasms: a clinical review. Front Biosci 11 (2006) 1466-1478
14. Fan Q.W., Cheng C., Knight Z.A., et al. EGFR signals to mTOR through PKC and independently of Akt in glioma [Erratum in: Sci Signal 2009;2(60):er4]. Sci Signal 2 55 (2009) ra4
15. Li L., Dutra A., Pak E., et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol 11 (2009) 9-21
16. Pore N., Liu S., Haas-Kogan D.A., O'Rourke D.M., and Maity A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 63 (2003) 236-241
17. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
18. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
19. Bachoo R.M., Maher E.A., Ligon K.L., et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1 (2002) 269-277
20. Holland E.C. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2 (2001) 120-129
21. Shannon P., Sabha N., Lau N., et al. Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol 167 (2005) 859-867
22. Wei Q., Clarke L., Scheidenhelm D.K., et al. High-grade glioma formation results from postnatal Pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 66 (2006) 7429-7437
23. Weiss W.A., Burns M.J., Hackett C., et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63 (2003) 1589-1595
24. Xiao A., Wu H., Pandolfi P.P., Louis D.N., and Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 1 (2002) 157-168
25. Zheng H., Ying H., Yan H., et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455 (2008) 1129-1133
26. Zhu Y., Guignard F., Zhao D., et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8 (2005) 119-130
27. Kwon C.H., Zhao D., Chen J., et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 68 (2008) 3286-3294
28. Sarkaria J.N., Yang L., Grogan P.T., et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 6 (2007) 1167-1174
29. Choe G., Horvath S., Cloughesy T.F., et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63 (2003) 2742-2746
30. Ermoian R.P., Furniss C.S., Lamborn K.R., et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8 (2002) 1100-1106
31. Riemenschneider M.J., Betensky R.A., Pasedag S.M., and Louis D.N. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 66 (2006) 5618-5623
32. Huang H.S., Nagane M., Klingbeil C.K., et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272 (1997) 2927-2935
33. Maruno M., Kovach J.S., Kelly P.J., and Yanagihara T. Transforming growth factor-alpha, epidermal growth factor receptor, and proliferating potential in benign and malignant gliomas. J Neurosurg 75 (1991) 97-102
34. Montgomery R.B., Moscatello D.K., Wong A.J., Cooper J.A., and Stahl W.L. Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 270 (1995) 30562-30566
35. Samuels V., Barrett J.M., Bockman S., Pantazis C.G., and Allen Jr. M.B. Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 134 (1989) 894-902
36. Wikstrand C.J., McLendon R.E., Friedman A.H., and Bigner D.D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57 (1997) 4130-4140
37. Yung W.K., Zhang X., Steck P.A., and Hung M.C. Differential amplification of the TGF-alpha gene in human gliomas. Cancer Commun 2 (1990) 201-205
38. Yoshimoto K., Dang J., Zhu S., et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 14 (2008) 488-493
39. Huang P.H., Mukasa A., Bonavia R., et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 104 (2007) 12867-12872
40. Frederick L., Eley G., Wang X.Y., and James C.D. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro Oncol 2 (2000) 159-163
41. Frederick L., Wang X.Y., Eley G., and James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60 (2000) 1383-1387
42. Lee J.C., Vivanco I., Beroukhim R., et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3 (2006) e485
43. Akbasak A., and Sunar-Akbasak B. Oncogenes: cause or consequence in the development of glial tumors. J Neurol Sci 111 (1992) 119-133
44. Mishima K., Johns T.G., Luwor R.B., et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61 (2001) 5349-5354
45. Yamoutpour F., Bodempudi V., Park S.E., et al. Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther 7 (2008) 3586-3597
46. Martens T., Laabs Y., Gunther H.S., et al. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res 14 (2008) 5447-5458
47. Haas-Kogan D.A., Prados M.D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97 (2005) 880-887
48. Doherty L., Gigas D.C., Kesari S., et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67 (2006) 156-158
49. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
50. Fan Q.W., Cheng C.K., Nicolaides T.P., et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67 (2007) 7960-7965
51. Wang M.Y., Lu K.V., Zhu S., et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66 (2006) 7864-7869
52. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 (2005) 357-361
53. Cloughesy T.F., Yoshimoto K., Nghiemphu P., et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5 (2008) e8
54. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
55. Nakamura J.L., Garcia E., and Pieper R.O. S6K1 plays a key role in glial transformation. Cancer Res 68 (2008) 6516-6523
56. Carracedo A., Baselga J., and Pandolfi P.P. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 7 (2008) 3805-3809
57. Carracedo A., Ma L., Teruya-Feldstein J., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118 (2008) 3065-3074
58. Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (2007) 287-290
59. Hambardzumyan D., Becher O.J., Rosenblum M.K., et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22 (2008) 436-448
60. Johannessen T.C., Bjerkvig R., and Tysnes B.B. DNA repair and cancer stem-like cells: potential partners in glioma drug resistance?. Cancer Treat Rev 34 (2008) 558-567
61. Li Z., Wang H., Eyler C.E., and Rich J.N. Turning cancer stem cells inside-out: an exploration of glioma stem cell signaling pathways. J Biol Chem (2009)
62. Bertrand J., Begaud-Grimaud G., Bessette B., et al. Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis. Int J Oncol 34 (2009) 717-727
63. INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res 68 (2008) 2564-2569
64. Yu Y., Jiang X., Schoch B.S., et al. Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res 67 (2007) 130-138
65. Glaser T., Wagenknecht B., and Weller M. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene 20 (2001) 4757-4767
66. Dinca E.B., Lu K.V., Sarkaria J.N., et al. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 68 (2008) 10034-10039
67. Parsa A.T., Waldron J.S., Panner A., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 (2007) 84-88
68. Gilbertson R.J., and Rich J.N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7 (2007) 733-736
69. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (2004) 133-142
70. Brown P.D., Krishnan S., Sarkaria J.N., et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26 (2008) 5603-5609
71. Brandes A.A., Franceschi E., Tosoni A., Hegi M.E., and Stupp R. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 14 (2008) 957-960
72. Wong T.W., Lee F.Y., Yu C., et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 12 (2006) 6186-6193
73. Neyns B., Sadones J., Joosens E., et al. A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. J Clin Oncol Meet Abstr 26 (2008) 2017 (abstract)
74. Cohenuram M., and Saif M.W. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18 (2007) 7-15
75. Bode U., Buchen S., Janssen G., et al. Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. J Clin Oncol Meet Abstr 24 (2006) 1522 (abstract)
76. Bode U., Buchen S., Warmuth-Metz M., et al. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol Meet Abstr 25 (2007) 2006 (abstract)
77. Schmiedel J., Blaukat A., Li S., Knochel T., and Ferguson K.M. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13 (2008) 365-373
78. Lammerts van Bueren J.J., Bleeker W.K., Brannstrom A., et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A 105 (2008) 6109-6114
79. Kuenen B., Witteveen E., Ruijter R., et al. A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors: interim results. ASCO Meet Abstr 24 (2006) 3024 (abstract)
80. Tabernero J., Sastre Valera J., Delaunoit T., et al. A phase II multicenter study evaluating the efficacy and safety of IMC-11F8, a recombinant human IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody (Mab), combined with 5-FU/FA and oxaliplatin (mFOLFOX-6) as first-line therapy. ASCO Meet Abstr 26 (2008) 4066 (abstract)
81. Johns T.G., Perera R.M., Vernes S.C., et al. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13 (2007) 1911-1925
82. Mineo J.F., Bordron A., Quintin-Roue I., et al. Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. Br J Cancer 91 (2004) 1195-1199
83. Beltran P.J., Mitchell P., Moody G., et al. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. ASCO Meet Abstr 26 (2008) 4617 (abstract)
84. Rowinsky E.K., Youssoufian H., Tonra J.R., et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13 (2007) 5549s-5555s
85. Higano C.S., Yu E.Y., Whiting S.H., et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol Meet Abstr 25 (2007) 3505 (abstract)
86. Karp D.D., Paz-Ares L.G., Novello S., et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. ASCO Meet Abstr 26 (2008) 8015 (abstract)
87. Cohen B.D., Baker D.A., Soderstrom C., et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11 (2005) 2063-2073
88. Matsumoto K., Nakamura T., and Sakai K. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics 8 (2008) 3360-3370
89. Mazzone M., Basilico C., Cavassa S., et al. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 114 (2004) 1418-1432
90. Kong-Beltran M., Stamos J., and Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6 (2004) 75-84
91. Michieli P., Mazzone M., Basilico C., et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6 (2004) 61-73
92. Compugen. CGEN-241: soluble variants of MET. Available at: http://www.cgen.com/data/uploads/Pdf/CGEN-241%20update%20September%204%2008.pdf. Accessed May 29, 2009.
93. Kim K.J., Wang L., Su Y.C., et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12 (2006) 1292-1298
94. Jun H.T., Sun J., Rex K., et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 13 (2007) 6735-6742
95. Martens T., Schmidt N.O., Eckerich C., et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12 (2006) 6144-6152
96. 18F-FDG small-animal PET. J Nucl Med 49 (2008) 129-134
97. Petrelli A., Circosta P., Granziero L., et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 103 (2006) 5090-5095
98. Bellon S.F., Kaplan-Lefko P., Yang Y., et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 283 (2008) 2675-2683
99. Garcia A., Rosen L., Cunningham C.C., et al. Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. J Clin Oncol Meet Abstr 25 (2007) 3525 (abstract)
100. Yap T.A., Harris D., Barriuso J., et al. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule. J Clin Oncol Meet Abstr 26 (2008) 3584 (abstract)
101. Camacho L.H., Moulder S.L., LoRusso P.M., et al. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. J Clin Oncol Meet Abstr 26 (2008) 14657 (abstract)
102. Welsh J., Mahadevan D., Bearss D., and Stea B. Sensitization of a glioblastoma multiforme (GBM) cell line by MP470: a novel c-Met antagonist. Int J Radiat Oncol Biol Phys 69 (2007) S100 (abstract)
103. Zou H.Y., Li Q., Lee J.H., et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67 (2007) 4408-4417
104. Christensen J.G., Schreck R., Burrows J., et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63 (2003) 7345-7355
105. Berthou S., Aebersold D.M., Schmidt L.S., et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23 (2004) 5387-5393
106. Sattler M., Pride Y.B., Ma P., et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 63 (2003) 5462-5469
107. Ross R.W., Stein M., Sarantopoulos J., et al. A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). J Clin Oncol Meet Abstr 25 (2007) 15601 (abstract)
108. Salgia R., Sherman S., Hong D.S., et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol Meet Abstr 26 (2008) 3522 (abstract)
109. Du J., Bernasconi P., Clauser K.R., et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 27 (2009) 77-83
110. Raymond E., Brandes A.A., Dittrich C., et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group study. J Clin Oncol 26 (2008) 4659-4665
111. Reardon D.A., Egorin M.J., Quinn J.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23 (2005) 9359-9368
112. Wen P.Y., Yung W.K., Lamborn K.R., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12 (2006) 4899-4907
113. Reardon D.A., Egorin M.J., Desjardins A., et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer (2009)
114. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729
115. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27 (2009) 740-745
116. Gomez-Manzano C., Holash J., Fueyo J., et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10 (2008) 940-945
117. De Groot J.F., Wen P.Y., Lamborn K., et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. J Clin Oncol Meet Abstr 26 (2008) 2020 (abstract)
118. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65 (2005) 4389-4400
119. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
120. Podar K., Tonon G., Sattler M., et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A 103 (2006) 19478-19483
121. Adnane L., Trail P.A., Taylor I., et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407 (2006) 597-612
122. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 (2002) 4645-4655
123. Heymach J.V., Paz-Ares L., De Braud F., et al. Randomized Phase II Study of Vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26 (2008) 5407-5415
124. Wells Jr. S.A., Gosnell J.E., Gagel R.F., et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. ASCO Meet Abstr 25 (2007) 6018
125. Kirkpatrick J.P., Rich J.N., Vredenburgh J.J., et al. Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). ASCO Meet Abstr 26 (2008) 2057 (abstract)